Document Type
Article
Publication Date
9-19-2022
Identifier
DOI: 10.1038/s41467-022-33244-6; PMCID: PMC9485122
Abstract
Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor outcomes and relapse risk prediction approaches have not changed significantly in decades. To build a robust transcriptional risk prediction model for pediatric AML, we perform RNA-sequencing on 1503 primary diagnostic samples. While a 17 gene leukemia stem cell signature (LSC17) is predictive in our aggregated pediatric study population, LSC17 is no longer predictive within established cytogenetic and molecular (cytomolecular) risk groups. Therefore, we identify distinct LSC signatures on the basis of AML cytomolecular subtypes (LSC47) that were more predictive than LSC17. Based on these findings, we build a robust relapse prediction model within a training cohort and then validate it within independent cohorts. Here, we show that LSC47 increases the predictive power of conventional risk stratification and that applying biomarkers in a manner that is informed by cytomolecular profiling outperforms a uniform biomarker approach.
Journal Title
Nat Commun
Volume
13
Issue
1
First Page
5487
Last Page
5487
MeSH Keywords
Biomarkers; Child; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; RNA; Recurrence
Keywords
Biomarkers; Gene Expression Profiling; Acute Myeloid Leukemia; Neoplastic Stem Cells; RNA; Recurrence
Recommended Citation
Huang BJ, Smith JL, Farrar JE, et al. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nat Commun. 2022;13(1):5487. Published 2022 Sep 19. doi:10.1038/s41467-022-33244-6
Comments
Grant support
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Link: https://www.nature.com/articles/s41467-022-33244-6